Amiloride

Amiloride has been studied in 11 papers since 2016: 5 trials and 1 observational study in people, 2 in animals, 2 in cells, 1 review; 7 in the past year. It is an approved medicine. The newest paper, Nov 13, 2026: “Amiloride in hypertension: mechanisms, clinical use and emerging perspectives”.

InterventionApproved 1981

11 papers study it4 more mention it20 findingsUpdated

PubChemChEBIMeSH

5 new papers in 30 daysSee all 15 papers on amiloride

At a glance

The findings reach people, from one lab or study. 5 independent labs in 4 countries; 26 trials, none about aging, 13 with no results posted.

“Amiloride significantly reduced arterial stiffness, with decreases in cfPWV at 12 and 24 wk”
ENAC blockade reduces blood pressure and arterial stiffness in adults with obesity and insulin resistanceAmerican journal of physiology. Heart and circulatory physiology2026doi:10.1152/ajpheart.00084.2026

None of its findings points the other way.

Cells, mice and humans: a single group. Worms or flies: nothing yet.
  • 5 independent labs in 4 countries
  • 26 trials, none about aging, 13 with no results posted
  • Funders: National Heart, Lung, and Blood Institute and others
  • Human trial5
  • Humans1
  • Animals2
  • Cells2

Studies in people

2 studies gave amiloride to people and measured what changed.

What changedDesignPeopleSource

no change: Has no effect on pulse wave velocity

down: Decreases 24-hour systolic blood pressure135 ± 11 to 130 ± 13 mm Hg

up: Increases plasma potassium

Randomized trial2 weeks37 peopleAdults; mean age 39 ± 11 yearsADPKD; both salt and low-salt groupsKidney international reports, Sep 23, 2026

down: Decreases arterial stiffness-0.23 m/s (95% CI -0.39 to -0.07) at 24 weeks

down: Decreases systolic blood pressure-5.59 mmHg (95% CI -8.10 to -3.08) at 24 weeks

down: Decreases glucose-6.07 mg/dL (95% CI -8.16 to -3.98) at 24 weeks

Randomized trial24 weeks137 people63.5% were womenmean age 47 yearsAdults with elevated adiposity and insulin resistance indicesAmerican journal of physiology. Heart and circulatory physiology, Mar 12, 2026

What did studies of amiloride find?

16

Studies of amiloride measured 16 outcomes, among them systolic blood pressure, glucose and arterial stiffness.

Systolic blood pressure

downin humans1downin mice1

2 studies
  1. Amiloride decreases systolic blood pressure in humans (-5.59 mmHg (95% CI -8.10 to -3.08) at 24 weeks).

    “For SBP, the amiloride group showed significant reductions of 2.96 mmHg at 12 weeks (95% CI −5.49 to −0.43; P < 0.05) and 5.59 mmHg at 24 weeks (95% CI −8.10 to −3.08; P < 0.05) relative to baseline.”

    Human trial24 weeks

    ENAC blockade reduces blood pressure and arterial stiffness in adults with obesity and insulin resistance

    American journal of physiology. Heart and circulatory physiology

  2. Amiloride decreases systolic blood pressure in adults with overweight or obesity and at least one metabolic syndrome feature (-5.6 mmHg).

    “Systolic blood pressure was also reduced, with a mean reduction of 5.6 mmHg at 24 wk.”

    Human trialin adults with overweight or obesity and at least one metabolic syndrome featurelow-dose5 mg daily24 wkn = 137

    ENAC blockade reduces blood pressure and arterial stiffness in adults with obesity and insulin resistance

    American journal of physiology. Heart and circulatory physiology

  3. Amiloride decreases systolic blood pressure in mice (Eln+/-).

    “amiloride lowered SBP and increased urinary Na+ excretion, suggesting that Eln+/--induced hypertension may be Na+-dependent.”

    AnimalsEln+/-females

    Ovarian hormones moderate systolic hypertension in female Eln haploinsufficient mice

    American journal of physiology. Renal physiology

Glucose

downin humans1

1 study
  1. Amiloride decreases glucose in humans (-6.07 mg/dL (95% CI -8.16 to -3.98) at 24 weeks).

    “Glucose concentrations in the amiloride group decreased by 3.22 mg/dL at 12 weeks (95% CI −5.33 to −1.11; P < 0.05) and by 6.07 mg/dL at 24 weeks (95% CI −8.16 to −3.98; P < 0.05) relative to baseline, with no influence of sex and age.”

    Human trial24 weeks

    ENAC blockade reduces blood pressure and arterial stiffness in adults with obesity and insulin resistance

    American journal of physiology. Heart and circulatory physiology

  2. Amiloride decreases glucose in adults with overweight or obesity and features of metabolic syndrome.

    “Amiloride increased serum potassium and lowered fasting glucose, but did not significantly affect brachial artery flow-mediated dilation.”

    Human trialin adults with overweight or obesity and features of metabolic syndromelow-dose5 mg daily24 wkn = 137

    ENAC blockade reduces blood pressure and arterial stiffness in adults with obesity and insulin resistance

    American journal of physiology. Heart and circulatory physiology

More on Glucose

Arterial stiffness

downin humans1

1 study
  1. Amiloride decreases arterial stiffness in humans (-0.23 m/s (95% CI -0.39 to -0.07) at 24 weeks).

    “cfPWV decreased in the amiloride group from baseline by 0.24 m/s (95% CI −0.41 to −0.07) at 12 weeks (P < 0.05) and by 0.23 m/s (95% CI −0.39 to −0.07) at 24 weeks (P < 0.05”

    Human trial24 weeks

    ENAC blockade reduces blood pressure and arterial stiffness in adults with obesity and insulin resistance

    American journal of physiology. Heart and circulatory physiology

  2. Amiloride decreases arterial stiffness in adults with overweight or obesity and at least one metabolic syndrome feature.

    “Amiloride significantly reduced arterial stiffness, with decreases in cfPWV at 12 and 24 wk”

    Human trialin adults with overweight or obesity and at least one metabolic syndrome featurelow-dose5 mg daily24 wkn = 137

    ENAC blockade reduces blood pressure and arterial stiffness in adults with obesity and insulin resistance

    American journal of physiology. Heart and circulatory physiology

Metabolic health

upin humans1

1 study
  1. Amiloride improves metabolic health in humans (compared with thiazide diuretics).

    “More recent trials demonstrated favourable metabolic effects compared with thiazide diuretics”

    Reviewcompared with thiazide diuretics

    Amiloride in hypertension: mechanisms, clinical use and emerging perspectives

    Drug and therapeutics bulletin

Blood pressure

downin humans1

1 study
  1. Amiloride decreases blood pressure in humans (hypertension, including resistant hypertension).

    “evidence from mechanistic and clinical studies suggesting efficacy in blood pressure reduction, including in resistant hypertension.”

    Reviewhypertension, including resistant hypertension

    Amiloride in hypertension: mechanisms, clinical use and emerging perspectives

    Drug and therapeutics bulletin

Endothelium-dependent vasodilation

upin mice1

1 study
  1. Amiloride improves endothelium-dependent vasodilation in mice.

    “This was accompanied by restoration of NO bioavailability, reduced monocyte adhesion, and marked improvement of endothelium-dependent vasodilation in exposed mouse aortic rings”

    Animalswild-type mouse tissue pretreated before exposure to polystyrene (2 μm, 200 μg/mL for 24 hours)isolated thoracic aortic ring20 μM

    Pharmacological inhibition of microplastic uptake prevents endothelial injury

    ESC Congress 2026 abstract

Nitric oxide bioavailability

upin human cells1

1 study
  1. Amiloride increases nitric oxide bioavailability in human cells (pretreatment before exposure to polystyrene (2 μm, 200 μg/mL for 24 hours)).

    “This was accompanied by restoration of NO bioavailability, reduced monocyte adhesion, and marked improvement of endothelium-dependent vasodilation in exposed mouse aortic rings”

    Cellspretreatment before exposure to polystyrene (2 μm, 200 μg/mL for 24 hours)human aortic endothelial cell20 μM

    Pharmacological inhibition of microplastic uptake prevents endothelial injury

    ESC Congress 2026 abstract

More on Nitric oxide bioavailability

Inflammation

downin human cells1

1 study
  1. Amiloride decreases inflammation in human cells (pretreatment before exposure to polystyrene (2 μm, 200 μg/mL for 24 hours)).

    “Pharmacological inhibition of PS uptake with amiloride in HAECs significantly reduced intracellular particle accumulation and attenuated oxidative and inflammatory signaling.”

    Cellspretreatment before exposure to polystyrene (2 μm, 200 μg/mL for 24 hours)human aortic endothelial cell20 μM

    Pharmacological inhibition of microplastic uptake prevents endothelial injury

    ESC Congress 2026 abstract

More on Inflammation

Oxidative stress and ROS signaling

downin human cells1

1 study
  1. Amiloride decreases oxidative stress and ROS signaling in human cells (pretreatment before exposure to polystyrene (2 μm, 200 μg/mL for 24 hours)).

    “Pharmacological inhibition of PS uptake with amiloride in HAECs significantly reduced intracellular particle accumulation and attenuated oxidative and inflammatory signaling.”

    Cellspretreatment before exposure to polystyrene (2 μm, 200 μg/mL for 24 hours)human aortic endothelial cell20 μM

    Pharmacological inhibition of microplastic uptake prevents endothelial injury

    ESC Congress 2026 abstract

More on Oxidative stress and ROS signaling

Intracellular polystyrene accumulation

downin human cells1

1 study
  1. Amiloride decreases intracellular polystyrene accumulation in human cells (pretreatment before exposure to polystyrene (2 μm, 200 μg/mL for 24 hours)).

    “Pharmacological inhibition of PS uptake with amiloride in HAECs significantly reduced intracellular particle accumulation and attenuated oxidative and inflammatory signaling.”

    Cellspretreatment before exposure to polystyrene (2 μm, 200 μg/mL for 24 hours)human aortic endothelial cell20 μM

    Pharmacological inhibition of microplastic uptake prevents endothelial injury

    ESC Congress 2026 abstract

Plasma potassium

upin humans1

1 study
  1. Amiloride increases plasma potassium in humans (ADPKD; both groups).

    “Plasma potassium increased modestly in both groups following amiloride, without hyperkalemia.”

    Human trialADPKD; both groups20 mg/d2 weeksn = 37

    Randomized Controlled Trial of Salt and Amiloride on Vascular Stiffness in ADPKD

    Kidney international reports

More on Plasma potassium

24-hour systolic blood pressure

downin humans1

1 study
  1. Amiloride decreases 24-hour systolic blood pressure in humans (ADPKD; low-salt group) (135 ± 11 to 130 ± 13 mm Hg).

    “amiloride significantly lowered BP only under low-salt conditions.”

    Human trialADPKD; low-salt group20 mg/d2 weeksn = 18

    Randomized Controlled Trial of Salt and Amiloride on Vascular Stiffness in ADPKD

    Kidney international reports

More on 24-hour systolic blood pressure

Pulse wave velocity

no changein humans1

1 study
  1. Amiloride showed no clear effect on pulse wave velocity in humans (ADPKD; both salt and low-salt groups).

    “Amiloride did not reduce PWV in either group”

    Human trialADPKD; both salt and low-salt groups20 mg/d2 weeksn = 37

    Randomized Controlled Trial of Salt and Amiloride on Vascular Stiffness in ADPKD

    Kidney international reports

More on Pulse wave velocity

Flow-mediated dilation

no changein humans1

1 study
  1. Amiloride showed no clear effect on flow-mediated dilation in humans.

    “Brachial artery FMD was not significantly changed by the amiloride intervention.”

    Human trial24 weeks

    ENAC blockade reduces blood pressure and arterial stiffness in adults with obesity and insulin resistance

    American journal of physiology. Heart and circulatory physiology

All 16

Has amiloride been tested in people?

0 of 26 about aging

Yes: 5 trials and 1 observational study in people have been published, and 26 trials are registered.

Approved

Repurposing

All 23

In trials

  • Triple negative breast neoplasm

    Phase 2Recruiting1 trial

  • Pharmacokinetic

    Early phase 1Completed1 trial

Stopped

  • NCT05079789TerminatedEdema

    Low recruiting rate and decision to evaluate as pilot study

Who is developing amiloride?

1 company: Eurofarma Laboratorios.

Companies
  • Eurofarma LaboratoriosPhase 3arterial hypertension

Trial sponsors

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 2Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 1Oct 2026: 3Nov 2026: 28 papers in 12 months
Acta Physiologica

Klotho deficiency disrupts potassium balance in mice

In Klotho-deficient mice, renal mTORC1 activation suppressed potassium channel ROMK1 to cause hyperkalemia, which rapamycin or Klotho supplementation reversed.In Klotho-deficient mice, renal mTORC1 activation suppressed potassium channel ROMK1 to cause hyperkalemia, which rapamycin or Klotho supplementation reversed.

Experiments in miceKL

See all 15 papers on amiloride